Peptide 101: What Are Peptides?

Category: Beginner Type: Guide Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/peptide-101-what-are-peptides

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol.

Overview

Peptides are short chains of amino acids — typically 2 to 50 residues long — linked together by peptide bonds. They sit in a middle layer of human biology: smaller and more mobile than full proteins, but larger and more structured than individual amino acids. That middle position is exactly what makes them interesting therapeutically.

Your body already runs on peptides. Insulin, glucagon, oxytocin, vasopressin, ghrelin, GLP-1, growth hormone-releasing hormone — these are all peptides your endocrine system manufactures on demand. They act as biological signals: instructions that tell cells when to grow, repair, secrete, contract, or shut down a pathway.

Therapeutic peptides take this same signaling logic and apply it externally. Instead of flooding the body with a broad-acting drug, a peptide binds to a specific receptor and nudges a specific pathway. That precision is the headline feature of peptide therapeutics — and the reason interest has exploded over the past decade, with over 80 peptide drugs approved globally and another 150+ in clinical trials at the time of the 2018 Lau & Dunn review.^[NaN]

This guide is the front door to everything else on Peptides.NYC. By the end of it you should understand:

• What a peptide actually is at the molecular level
• How peptides differ from proteins, hormones, and small-molecule drugs
• The major therapeutic classes and what they target
• How peptides are administered, dosed, and regulated
• The vocabulary you need to read every other guide on this site

Why This Matters Now

Three forces have converged to make peptides one of the most-discussed categories in personal health optimization:

1. GLP-1 mainstreaming. Semaglutide and tirzepatide turned peptide therapy from a niche biohacking topic into front-page news. Once millions of people learned that a once-weekly injection could drive 15–20% weight loss, the broader peptide conversation became impossible to ignore.
2. Practitioner access. A growing number of longevity clinics, functional medicine practices, and concierge physicians now prescribe peptides for goals beyond traditional disease indications — recovery, sleep, body composition, cognition.
3. Research velocity. New peptide candidates are entering trials at a faster rate than at any point in the past 30 years, and synthesis costs have fallen sharply, expanding what's economically viable.

The combination is producing both real breakthroughs and real noise. The goal of this article is to give you the framework to tell them apart.

A Brief History of Peptide Therapeutics

Peptide medicine is older than most people realize. Understanding the timeline helps explain why the field looks the way it does today.

• 1921 — Insulin. Frederick Banting and Charles Best isolated insulin from canine pancreas, making it the first peptide therapy in clinical use. It immediately transformed type 1 diabetes from a death sentence into a manageable condition.
• 1950s — Sequencing. Frederick Sanger determined the full amino acid sequence of insulin, earning the 1958 Nobel Prize and proving that peptides had defined, decodable structures.
• 1960s–70s — Synthetic peptides. Bruce Merrifield developed solid-phase peptide synthesis, which let chemists build custom peptide sequences in the lab. This unlocked everything that followed.
• 1980s — Recombinant production. Recombinant DNA technology made it possible to brew human insulin in bacteria, ending dependence on animal pancreas extracts.
• 1990s–2000s — Targeted therapies. GnRH analogs (leuprolide), somatostatin analogs (octreotide), and calcitonin entered clinical use. Research-grade peptides like BPC-157, TB-500, and the growth hormone secretagogue family emerged from academic labs.
• 2005 — Exenatide. The first GLP-1 receptor agonist was approved for type 2 diabetes, opening the metabolic peptide era.
• 2017–2021 — Semaglutide. Approved first for diabetes, then for obesity, semaglutide demonstrated that peptide therapies could drive 15%+ weight loss and reshape an entire therapeutic category.
• 2022 — Tirzepatide. A dual GIP/GLP-1 agonist with even stronger metabolic effects, signaling the rise of multi-receptor peptides.
• 2023–2024 — Regulatory tightening. The FDA moved several popular research peptides (including BPC-157 and CJC-1295) to Category 2 of the 503A bulks list, restricting compounding pharmacy access in the U.S.

The throughline: peptide therapeutics started as life-saving hormone replacement, evolved into targeted disease treatments, and have now entered the broader optimization and longevity conversation.

How Peptides Differ From Proteins

People often use "peptide" and "protein" interchangeably. They shouldn't. Both are chains of amino acids, but they behave very differently in the body.

The dividing line at "50 amino acids" is a convention, not a hard rule. Insulin is technically a 51-amino-acid molecule made of two chains and is usually called a peptide hormone. The category matters less than the function: peptides primarily signal, proteins primarily do.

The Major Peptide Classes

Therapeutic peptides cluster into a handful of functional families. Knowing the families is the fastest way to map any individual peptide onto what it actually does.

Most peptides fit cleanly into one class. A few — like GHK-Cu, which shows up in both healing and longevity discussions — span multiple categories because they touch multiple pathways.

How Peptides Work in the Body

The mechanics of peptide action come down to a four-step loop: bind, signal, act, clear.

1. Receptor binding. A peptide circulates until it encounters a receptor it fits — usually a G-protein-coupled receptor (GPCR) or a receptor tyrosine kinase on a cell surface. The lock-and-key fit is what gives peptides their specificity.
2. Signal transduction. Binding triggers a conformational change in the receptor, which activates intracellular messengers like cAMP, IP3, or kinase cascades. The cell now "knows" a signal has arrived.
3. Cellular response. The signal drives a biological action: gene transcription, protein synthesis, secretion of another hormone, contraction, migration, or apoptosis. This is where the therapeutic effect actually happens.
4. Clearance. Enzymes called peptidases chop the peptide back into its component amino acids, which are recycled. Most peptides have half-lives measured in minutes to hours, which is why dosing frequency matters so much.

Half-life is one of the most important concepts in peptide therapy. A short half-life (like native GHRH, ~7 minutes) means frequent dosing. A long half-life (like semaglutide, ~1 week) means once-weekly injections. Drug developers spend enormous effort modifying peptides — adding fatty acid chains, swapping amino acids, attaching polymers — specifically to extend half-life without losing receptor affinity.

A few additional mechanisms worth knowing:

• Pulsatile vs. tonic signaling. Some hormones (like growth hormone) are released in pulses, and the rhythm of the pulses matters as much as the total dose. Secretagogues that preserve pulsatility tend to produce better outcomes than continuous infusion.
• Feedback loops. The endocrine system runs on negative feedback. Push a pathway too hard and the body downregulates receptors or shuts off upstream signals. This is why cycling and conservative dosing matter.
• Tissue distribution. Some peptides act locally near the injection site; others travel systemically. This dictates whether you inject near a target tissue or anywhere convenient.

Why Peptides Are Considered More Targeted Than Drugs

Traditional small-molecule drugs are powerful but often blunt. A statin lowers cholesterol by inhibiting an enzyme that exists in many tissues. An SSRI affects serotonin systems throughout the brain and gut. The trade-off for efficacy is a long list of off-target effects.

Peptides take a different approach:

• High receptor specificity. A peptide built around a natural ligand binds primarily to that ligand's receptor. Off-target binding is rare compared to small molecules.
• Physiological dosing. Many peptide protocols aim to restore or amplify the body's own signaling rather than override it. This is closer to hormesis — a gentle nudge — than to the heroic dosing common with pharmaceuticals.
• Endogenous mimicry. Because peptides resemble molecules your body already makes, they tend to be metabolized cleanly into amino acids without toxic byproducts.
• Pathway selectivity. A growth hormone secretagogue, for example, triggers pulsatile GH release that preserves natural feedback loops. Injecting recombinant HGH directly bypasses those loops entirely.

The trade-off is delivery. Most peptides can't be swallowed because the gut digests them. They require injection, intranasal delivery, or specialized formulations — which is why the next section matters.

Routes of Administration

How a peptide enters the body shapes how it works. Each route has trade-offs in bioavailability, convenience, and patient comfort.

• Subcutaneous (SC) injection. The default route for most peptides. A short, fine insulin needle delivers the peptide into the fatty layer beneath the skin, where it absorbs over minutes to hours. Belly, thigh, and the back of the upper arm are standard sites. Bioavailability is typically 70–95%.
• Intramuscular (IM) injection. Used occasionally for deeper tissue effects or for peptides requiring faster absorption. Less common in self-administered protocols.
• Intranasal sprays. Used for peptides that cross the nasal mucosa well — Semax, Selank, PT-141, and oxytocin are common examples. Bioavailability is lower (10–30%) but the route is needle-free and convenient.
• Sublingual / buccal. Drops or troches held under the tongue. Bypasses first-pass liver metabolism. Bioavailability varies widely; some peptides tolerate it, most don't.
• Topical. Used for peptides targeting skin or local tissue — GHK-Cu in cosmetic formulations is the canonical example.
• Oral. Limited but expanding. Most peptides are destroyed by stomach acid and digestive enzymes. Exceptions include BPC-157 (stable in gastric juice), oral semaglutide (Rybelsus, with absorption enhancers), and a handful of cyclic or modified peptides.

Reconstitution — mixing a lyophilized (freeze-dried) peptide powder with bacteriostatic water before use — is part of nearly every injection-based protocol. See our Reconstitution Cheat Sheet for the math.

Quick Bioavailability Reference

Reading a Peptide's Name

Peptide names look intimidating until you learn the patterns. A few common conventions:

• Number suffixes often indicate amino acid count or research lot. BPC-157 = Body Protection Compound, 15 residues from position 157 of a larger protein. TB-500 is a fragment of Thymosin Beta-4. AOD-9604 is the Anti-Obesity Drug at position 9604.
• Letter codes can spell out the amino acid sequence in single-letter code. KPV = Lysine-Proline-Valine. GHK-Cu = Glycine-Histidine-Lysine bound to copper.
• "-relin" suffix marks growth hormone-releasing peptides: Sermorelin, Ipamorelin, Tesamorelin, Hexarelin.
• "-tide" suffix marks larger therapeutic peptides, especially GLP-1 class: Semaglutide, Tirzepatide, Liraglutide, Retatrutide.
• "GHRP-X" = Growth Hormone Releasing Peptide, with the number indicating sequence variant (GHRP-2, GHRP-6).
• Greek letters are common in immune and longevity peptides: Thymosin Alpha-1, Thymosin Beta-4.

Once you spot the pattern, you can usually predict roughly what a peptide does just from its name.

A few additional naming tells worth knowing: peptides with "-pressin" (vasopressin, desmopressin) act on water balance and blood pressure. Peptides with "-tocin" (oxytocin) are related to the posterior pituitary family. Anything labeled "PT-" is usually a Palatin Technologies research compound (PT-141, PT-101). And "MOTS-" and "SS-" prefixes appear on the new generation of mitochondrial-derived peptides.

Regulatory Landscape

Peptide regulation in the United States is layered and changing. Understanding the categories helps you read every other resource on this site.

• FDA-approved peptides. Used in conventional medicine, prescribed for specific indications, manufactured under cGMP. Examples: insulin, semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide, leuprolide, octreotide, oxytocin, teriparatide.
• Compounded peptides. Made by 503A or 503B compounding pharmacies under prescription. Historically the access path for peptides like sermorelin, ipamorelin, BPC-157, and CJC-1295. In late 2023 the FDA moved several of these to Category 2 of the 503A bulks list, citing safety concerns and restricting their compounding.
• Research chemicals. Sold for "research use only," not for human consumption. This is the gray-market channel many enthusiasts have used historically. Quality varies enormously between vendors — purity, sterility, and accurate labeling are not guaranteed.
• International / clinic access. Some peptides are easier to obtain through international pharmacies or licensed practitioners operating under specific frameworks.

The regulatory picture is fluid. What's compoundable today may not be tomorrow, and what's research-only today may be approved later. Always verify current status before assuming access.

Outside the U.S., regulation varies sharply. Australia and the UK treat most research peptides as prescription-only. Several European countries have specific frameworks for compounded peptides. In some jurisdictions, peptides that are difficult to obtain domestically are routinely available through licensed pharmacies. This is one reason peptide tourism — traveling for clinical access — has become a real phenomenon among optimizers.

Are Peptides Safe?

Most peptides have favorable short-term safety profiles when sourced and used correctly. That said, "safe" is not the same as "risk-free," and the honest answer requires nuance.

What we know:

• Peptides are generally well-tolerated. Most common side effects are mild and transient: injection site reactions, mild nausea, headache, water retention, or temporary fatigue.
• Source and purity matter enormously. Underdosed, contaminated, or improperly stored peptides cause more problems than the peptides themselves.
• Long-term safety data is limited for many research peptides. We have decades of data on insulin and growing data on GLP-1s, but most other peptides have only small clinical studies behind them.

Common contraindications and caveats:

• Active or recent cancer. Peptides that promote angiogenesis or cell proliferation (BPC-157, TB-500, growth hormone secretagogues) are typically avoided.
• Pregnancy and breastfeeding. Almost no peptides have safety data in this population. Default answer is no.
• Children and adolescents. Generally not used outside of FDA-approved indications.
• Drug interactions. GLP-1s can affect absorption of oral medications. Growth hormone peptides can alter insulin sensitivity. Always disclose all peptides to prescribing physicians.

The single biggest safety lever is working with a knowledgeable practitioner who can run baseline labs, monitor response, and adjust protocols. See our Practitioner Directory for verified providers.

Baseline labs worth considering before most peptide protocols include a complete metabolic panel, lipid panel, fasting insulin and glucose, HbA1c, CBC, IGF-1 (for GH-axis peptides), sex hormones, and inflammatory markers like hs-CRP. Re-check at 8–12 weeks to compare. Without baseline numbers you have no way to know whether the protocol is actually doing what you wanted.

Common Goals + Which Peptides Fit Them

This is the cheat sheet most newcomers actually want. Use it to triage your interest — then read the dedicated guide for each peptide before doing anything.

This table is a map, not a prescription. Every peptide listed has specific dosing, timing, and stacking considerations covered in its dedicated guide.

What's Next

You now have the conceptual foundation. The natural next steps:

• Beginner's Stack Guide — your first 8–12 weeks: which peptides actually make sense as a starting protocol.
• First Injection Guide — step-by-step walkthrough of your first subcutaneous injection, with photos.
• Peptide Safety Guide — what to monitor, when to stop, red flags, and how to set up baseline labs.
• Reconstitution Cheat Sheet — the math behind mixing peptides correctly.
• Peptide Glossary — full vocabulary reference for the rest of the library.

If you're not sure where to start, the Peptide Navigator Quiz maps your goals to a recommended learning path in about three minutes.

Glossary of Terms

• Amino acid — The building block of peptides and proteins. There are 20 standard amino acids in human biology, each with a one- and three-letter code (e.g., Lysine = K = Lys).
• Peptide bond — The covalent linkage between two amino acids, formed by joining a carboxyl group to an amino group with release of water.
• Half-life — The time it takes for half of a dose to be cleared from the body. Drives how often you need to dose.
• Secretagogue — A substance that triggers the release of another substance from a gland. Growth hormone secretagogues (sermorelin, ipamorelin) trigger your pituitary to release its own GH.
• Agonist — A molecule that binds a receptor and activates it. GLP-1 agonists like semaglutide turn on the GLP-1 receptor. Opposite of antagonist (blocks the receptor).
• Ghrelin — A peptide hormone made in the stomach that drives hunger and stimulates growth hormone release. Many GH-axis peptides target the ghrelin receptor.
• Subcutaneous (SC) — Beneath the skin, into the fatty layer. The standard injection route for most peptides.
• Reconstitute — To dissolve a lyophilized (freeze-dried) peptide powder in bacteriostatic water to create an injectable solution.
• Bioavailability — The percentage of a dose that actually reaches systemic circulation. Subcutaneous injection ≈ 70–95%; oral ≈ 1–5% for most peptides.
• GPCR — G-protein-coupled receptor. The most common receptor family targeted by peptide drugs; runs about a third of all FDA-approved drug interactions.
• COA (Certificate of Analysis) — Third-party lab report verifying a peptide's identity, purity, and absence of contaminants. Non-negotiable when sourcing.
• Hormesis — The principle that small, controlled doses of a stressor produce beneficial adaptations. Peptide therapy often operates here rather than at "heroic" pharmaceutical doses.

Related Content

• Beginner's Stack Guide
• Peptide Glossary
• First Injection Guide
• Peptide Safety Guide
• Reconstitution Cheat Sheet
• BPC-157 Complete Guide
• GLP-1 Comparison Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Many peptides discussed are research compounds not FDA-approved for human use. Consult a licensed healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/peptide-101-what-are-peptides